NMR determination of Electrophorus electricus acetylcholinesterase inhibition and reactivation by neutral oximes. 2013

Sibelle Feitosa da Cunha Xavier Soares, and Andréia Aguiar Vieira, and Reinaldo Teixeira Delfino, and José Daniel Figueroa-Villar
Medicinal Chemistry Group, Chemistry Department, Military Institute of Engineering, Rio de Janeiro, Brazil.

Neurotoxic organophosphorus compounds (OPs), which are used as pesticides and chemical warfare agents lead to more than 700,000 intoxications worldwide every year. The main target of OPs is the inhibition of acetylcholinesterase (AChE), an enzyme necessary for the control of the neurotransmitter acetylcholine (ACh). The control of ACh function is performed by its hydrolysis with AChE, a process that can be completely interrupted by inhibition of the enzyme by phosphylation with OPs. Compounds used for reactivation of the phosphylated AChE are cationic oximes, which usually possess low membrane and hematoencephalic barrier permeation. Neutral oximes possess a better capacity for hematoencephalic barrier permeation. NMR spectroscopy is a very confident method for monitoring the inhibition and reactivation of enzymes, different from the Ellman test, which is the common method for evaluation of inhibition and reactivation of AChE. In this work (1)H NMR was used to test the effect of neutral oximes on inhibition of AChE and reactivation of AChE inhibited with ethyl-paraoxon. The results confirmed that NMR is a very efficient method for monitoring the action of AChE, showing that neutral oximes, which display a significant AChE inhibition activity, are potential drugs for Alzheimer disease. The NMR method showed that a neutral oxime, previously indicated by the Ellman test as better in vitro reactivator of AChE inhibited with paraoxon than pralidoxime (2-PAM), was much less efficient than 2-PAM, confirming that NMR is a better method than the Ellman test.

UI MeSH Term Description Entries
D009682 Magnetic Resonance Spectroscopy Spectroscopic method of measuring the magnetic moment of elementary particles such as atomic nuclei, protons or electrons. It is employed in clinical applications such as NMR Tomography (MAGNETIC RESONANCE IMAGING). In Vivo NMR Spectroscopy,MR Spectroscopy,Magnetic Resonance,NMR Spectroscopy,NMR Spectroscopy, In Vivo,Nuclear Magnetic Resonance,Spectroscopy, Magnetic Resonance,Spectroscopy, NMR,Spectroscopy, Nuclear Magnetic Resonance,Magnetic Resonance Spectroscopies,Magnetic Resonance, Nuclear,NMR Spectroscopies,Resonance Spectroscopy, Magnetic,Resonance, Magnetic,Resonance, Nuclear Magnetic,Spectroscopies, NMR,Spectroscopy, MR
D010091 Oximes Compounds that contain the radical R2C Aldoximes,Hydroxyimino Compounds,Ketoxime,Ketoximes,Oxime,Compounds, Hydroxyimino
D010261 Paraoxon An organophosphate cholinesterase inhibitor that is used as a pesticide. Diethyl-p-Nitrophenyl Phosphate,E-600,Fosfakol,Phosphacol,Diethyl p Nitrophenyl Phosphate,E 600,E600,Phosphate, Diethyl-p-Nitrophenyl
D010766 Phosphorylation The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety. Phosphorylations
D002800 Cholinesterase Inhibitors Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system. Acetylcholinesterase Inhibitor,Acetylcholinesterase Inhibitors,Anti-Cholinesterase,Anticholinesterase,Anticholinesterase Agent,Anticholinesterase Agents,Anticholinesterase Drug,Cholinesterase Inhibitor,Anti-Cholinesterases,Anticholinesterase Drugs,Anticholinesterases,Cholinesterase Inhibitors, Irreversible,Cholinesterase Inhibitors, Reversible,Agent, Anticholinesterase,Agents, Anticholinesterase,Anti Cholinesterase,Anti Cholinesterases,Drug, Anticholinesterase,Drugs, Anticholinesterase,Inhibitor, Acetylcholinesterase,Inhibitor, Cholinesterase,Inhibitors, Acetylcholinesterase,Inhibitors, Cholinesterase,Inhibitors, Irreversible Cholinesterase,Inhibitors, Reversible Cholinesterase,Irreversible Cholinesterase Inhibitors,Reversible Cholinesterase Inhibitors
D002801 Cholinesterase Reactivators Drugs used to reverse the inactivation of cholinesterase caused by organophosphates or sulfonates. They are an important component of therapy in agricultural, industrial, and military poisonings by organophosphates and sulfonates. Insecticides, Organophosphate, Antagonists,Insecticides, Organothiophosphate, Antagonists,Organophosphate Insecticide Antagonists,Organothiophosphate Insecticide Antagonists,Antagonists, Organophosphate Insecticide,Antagonists, Organothiophosphate Insecticide,Insecticide Antagonists, Organophosphate,Insecticide Antagonists, Organothiophosphate,Reactivators, Cholinesterase
D004593 Electrophorus A genus of fish, in the family GYMNOTIFORMES, capable of producing an electric shock that immobilizes fish and other prey. The species Electrophorus electricus is also known as the electric eel, though it is not a true eel. Eel, Electric,Electric Eel,Electrophorus electricus
D000110 Acetylcholinesterase An enzyme that catalyzes the hydrolysis of ACETYLCHOLINE to CHOLINE and acetate. In the CNS, this enzyme plays a role in the function of peripheral neuromuscular junctions. EC 3.1.1.7. Acetylcholine Hydrolase,Acetylthiocholinesterase,Hydrolase, Acetylcholine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

Sibelle Feitosa da Cunha Xavier Soares, and Andréia Aguiar Vieira, and Reinaldo Teixeira Delfino, and José Daniel Figueroa-Villar
June 1990, Archives of biochemistry and biophysics,
Sibelle Feitosa da Cunha Xavier Soares, and Andréia Aguiar Vieira, and Reinaldo Teixeira Delfino, and José Daniel Figueroa-Villar
September 2002, The international journal of biochemistry & cell biology,
Sibelle Feitosa da Cunha Xavier Soares, and Andréia Aguiar Vieira, and Reinaldo Teixeira Delfino, and José Daniel Figueroa-Villar
April 1982, Biochemical pharmacology,
Sibelle Feitosa da Cunha Xavier Soares, and Andréia Aguiar Vieira, and Reinaldo Teixeira Delfino, and José Daniel Figueroa-Villar
September 1978, Archives of biochemistry and biophysics,
Sibelle Feitosa da Cunha Xavier Soares, and Andréia Aguiar Vieira, and Reinaldo Teixeira Delfino, and José Daniel Figueroa-Villar
August 1976, FEBS letters,
Sibelle Feitosa da Cunha Xavier Soares, and Andréia Aguiar Vieira, and Reinaldo Teixeira Delfino, and José Daniel Figueroa-Villar
May 1982, Biochimica et biophysica acta,
Sibelle Feitosa da Cunha Xavier Soares, and Andréia Aguiar Vieira, and Reinaldo Teixeira Delfino, and José Daniel Figueroa-Villar
August 1995, European journal of biochemistry,
Sibelle Feitosa da Cunha Xavier Soares, and Andréia Aguiar Vieira, and Reinaldo Teixeira Delfino, and José Daniel Figueroa-Villar
December 1973, FEBS letters,
Sibelle Feitosa da Cunha Xavier Soares, and Andréia Aguiar Vieira, and Reinaldo Teixeira Delfino, and José Daniel Figueroa-Villar
June 2003, Protein and peptide letters,
Sibelle Feitosa da Cunha Xavier Soares, and Andréia Aguiar Vieira, and Reinaldo Teixeira Delfino, and José Daniel Figueroa-Villar
January 1996, Zeitschrift fur Naturforschung. C, Journal of biosciences,
Copied contents to your clipboard!